Selloff or Market Correction? Either Way, Here's What to Do NextSee Overvalued Stocks

Walgreens weathers slowing COVID vaccination with higher retail sales

Published 10/13/2022, 07:09 AM
Updated 10/13/2022, 11:26 AM
© Reuters. People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly
US90274J5618=UBSS
-

By Mrinalika Roy and Raghav Mahobe

(Reuters) - Walgreens Boots Alliance (NASDAQ:WBA) Inc reported a better-than-expected quarterly profit on Thursday, as higher UK retail sales helped more than offset waning COVID vaccination demand.

Shares of Walgreens, one of the largest U.S. pharmacies, rose nearly 3% amid bigger market weakness after the company also forecast a "better-than-feared" full-year profit.

Analysts had raised concerns about Walgreens' near-term performance and lowered their expectations, especially after rival Rite Aid (NYSE:RAD) cut its full-year forecast last month and flagged concerns of sustained pressure on consumer spending and supply chain challenges.

Despite inflationary challenges, Walgreens saw an uptick in retail sales, helped by higher demand for health and wellness as well as beauty products.

"With inflation at four-decade highs, consumers are expressing uncertainty about the future and seeking value. At the same time, we know that health and wellness will always be a priority and increasingly so after COVID-19," Chief Executive Officer Rosalind Brewer said.

The company also benefited from its Walgreens Health segment, which was launched last year as part of Walgreens' efforts to diversify its business. The unit brought in sales of $622 million in the fourth quarter.

The company now expects full-year profit in the range of $4.45 to $4.65 per share, the top end of which came above analysts' expectations of $4.53.

J.P.Morgan analyst Lisa Gill said the forecast "will alleviate some concerns as guidance was above the feared number of below $4".

Pharmacy sales, however, continued to be pressured in the quarter due to waning COVID vaccination demand and lower prescription volumes as staffing issues impacted pharmacy hours.

The company said it expects prescription volumes to recover next year but warned that "lower COVID activity would continue to be a sizeable headwind."

© Reuters. FILE PHOTO: People are seen shopping in a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. REUTERS/Andrew Kelly/File Photo

Walgreens estimates it will administer 16 million vaccinations next year, compared to 35 million this year.

Excluding items, the company earned $0.80 per share in the quarter, compared with Refinitiv IBES estimates of $0.77.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.